$AVXL
ANAVEX LIFE SCIENCES CORP. Stock $avxl

$avxl Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000173112223000845 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.248M	$2.883M	$2.915M
YoY Change	1.96%	-1.12%	30.72%
% of Gross Profit
Research & Development	$10.28M	$11.31M	$8.605M
YoY Change	10.89%	31.4%	28.04%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$13.53M	$14.19M	$11.52M
YoY Change	8.6%	23.17%	28.71%
Operating Profit	-$13.53M	-$14.19M	-$11.52M
YoY Change	8.6%	23.17%
Interest Expense	$1.727M	$382.2K	$276.2K
YoY Change	-443.57%	38.36%	-284.15%
% of Operating Profit
Other Income/Expense, Net	$2.292M	$1.132M	$835.5K
YoY Change	235.82%	35.47%	-13.86%
Pretax Income	-$11.24M	-$13.06M	-$10.41M
YoY Change	-8.47%	25.45%	28.02%
Income Tax	$41.00K	$50.00K	$29.80K
% Of Pretax Income
Net Earnings	-$11.28M	-$13.11M	-$10.44M
YoY Change	-8.79%	25.57%	27.91%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.14	-$0.17
Diluted Earnings Per Share	-$0.14	-$0.17	-$136.9K
COMMON SHARES
Basic Shares Outstanding	80.84M shares	78.03M shares
Diluted Shares Outstanding	80.88M shares	78.30M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$154.8M	$153.5M	$153.3M
YoY Change	1.06%	0.08%	102.14%
Cash & Equivalents	$154.8M	$153.5M	$153.3M
Short-Term Investments
Other Short-Term Assets	$827.6K	$981.8K	$464.6K
YoY Change	79.14%	111.31%	19.13%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$157.8M	$159.2M	$160.3M
YoY Change	-1.5%	-0.68%	91.79%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$3.00	-$3.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$157.8M	$159.2M	$160.3M
Total Long-Term Assets	$3.00	-$3.00	$0.00
Total Assets	$157.8M	$159.2M	$160.3M
YoY Change	-1.5%	-0.68%	91.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.153M	$6.282M	$2.632M
YoY Change	32.81%	138.68%	-28.09%
Accrued Expenses	$5.986M	$6.823M	$4.995M
YoY Change	1.21%	36.58%	37.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.06M	$14.02M	$8.071M
YoY Change	16.56%	73.72%	4.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.06M	$14.02M	$8.071M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$11.06M	$14.02M	$8.071M
YoY Change	16.56%	73.72%	4.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$282.9M	-$271.6M
YoY Change
Common Stock	$429.7M	$416.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$146.8M	$145.2M	$152.2M
YoY Change
Total Liabilities & Shareholders Equity	$157.8M	$159.2M	$160.3M
YoY Change	-1.5%	-0.68%	91.79%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$11.28M	-$13.11M	-$10.44M
YoY Change	-8.79%	25.57%	27.91%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$7.653M	-$8.489M	-$9.639M
YoY Change	8.49%	-11.94%	31.69%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$12.21M
YoY Change			-66.72%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.003M	18.33M	11.84M
YoY Change	30.28%	54.9%	-66.96%
NET CHANGE
Cash From Operating Activities	-7.653M	-8.489M	-9.639M
Cash From Investing Activities
Cash From Financing Activities	9.003M	18.33M	11.84M
Net Change In Cash	1.350M	9.845M	2.196M
YoY Change	-1042.88%	348.28%	-92.29%
FREE CASH FLOW
Cash From Operating Activities	-$7.653M	-$8.489M	-$9.639M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	avxl	Option Issued OptionIssued	3916000	shares
CY2022Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	3192580	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001314052
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
	avxl	Non Operating Income From Grants NonOperatingIncomeFromGrants		usd
	avxl	Other Financing Expense OtherFinancingExpense		usd
CY2023Q1	avxl	Shares Issued Under2023 Purchase Agreement SharesIssuedUnder2023PurchaseAgreement		usd
CY2023Q1	avxl	Commitment Shares CommitmentShares		usd
	avxl	Commitment Shares CommitmentShares		usd
	avxl	Noncash Financing Related Charges NoncashFinancingRelatedCharges		usd
	avxl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome		usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37606
	dei	Entity Registrant Name EntityRegistrantName	ANAVEX LIFE SCIENCES CORP.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0608404
	dei	Entity Address Address Line1 EntityAddressAddressLine1	630 5th Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	20th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Country EntityAddressCountry	US
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10111
	dei	City Area Code CityAreaCode	844
	dei	Local Phone Number LocalPhoneNumber	689-3939
	dei	Security12b Title Security12bTitle	Common Stock Par Value $0.001
	dei	Trading Symbol TradingSymbol	AVXL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	80837723	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	153466962	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	149157861	usd
CY2023Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	4737661	usd
	us-gaap	Operating Expenses OperatingExpenses	29573114	usd
	us-gaap	Operating Expenses OperatingExpenses	23243137	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	981774	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	354162	usd
CY2023Q1	us-gaap	Assets Assets	159186397	usd
CY2022Q3	us-gaap	Assets Assets	152704603	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6281742	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3824777	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6822838	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5944953	usd
CY2023Q1	us-gaap	Deferred Income Current DeferredIncomeCurrent	916763	usd
CY2022Q3	us-gaap	Deferred Income Current DeferredIncomeCurrent	443831	usd
CY2023Q1	us-gaap	Liabilities Liabilities	14021343	usd
CY2022Q3	us-gaap	Liabilities Liabilities	10213561	usd
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	80235398	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	80235398	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77942815	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77942815	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	80236	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	77944	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	416727598	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	387976881	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-271642780	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-245563783	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	145165054	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	142491042	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	159186397	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152704603	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2882568	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2915158	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6199604	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5982109	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11306591	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8604589	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23373510	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17261028	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	14189159	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	11519747	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14189159	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11519747	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	146367706	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-29573114	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23243137	usd
	avxl	Non Operating Income From Grants NonOperatingIncomeFromGrants	25000	usd
CY2023Q1	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	749681	usd
CY2022Q1	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	835513	usd
	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	1483271	usd
	avxl	Research And Development Incentive Income ResearchAndDevelopmentIncentiveIncome	1646243	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1465221	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	7578	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2732839	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	12488	usd
CY2023Q1	avxl	Other Financing Expense OtherFinancingExpense	-964344	usd
	avxl	Other Financing Expense OtherFinancingExpense	-964344	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-118678	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	268645	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	247305	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	324008	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1131880	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1111736	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3524071	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1982739	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13057279	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10408011	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26049043	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21260398	usd
CY2023Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	50000	usd
CY2022Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	29800	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	29954	usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	59780	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13107279	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10437811	usd
	us-gaap	Net Income Loss NetIncomeLoss	-26078997	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21320178	usd
CY2023Q1	avxl	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.17
CY2022Q1	avxl	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.14
	avxl	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.33
	avxl	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.28
CY2023Q1	avxl	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	78304363
CY2022Q1	avxl	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	76248603
	avxl	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	78138940
	avxl	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	76121792
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	135124076	usd
CY2023Q1	avxl	Initial Commitment Shares InitialCommitmentShares	844500	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	18152500	usd
CY2023Q1	avxl	Shares Issued Pursuant To Exercise Of Stock Options SharesIssuedPursuantToExerciseOfStockOptions	181193	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3970064	usd
CY2022Q1	avxl	Shares Issued Pursuant To Exercise Of Stock Options SharesIssuedPursuantToExerciseOfStockOptions	123426	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13107279	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	145165054	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152107745	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	12086984	usd
CY2022Q1	avxl	Less Share Issue Costs LessShareIssueCosts	-374720	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4439456	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-10437811	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	152205041	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	142491042	usd
	avxl	Initial Commitment Shares InitialCommitmentShares	844500	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	18152500	usd
	avxl	Shares Issued Pursuant To Exercise Of Stock Options SharesIssuedPursuantToExerciseOfStockOptions	439437	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9316572	usd
	us-gaap	Net Income Loss NetIncomeLoss	-26078997	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	145165054	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	150818104	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	14399768	usd
	avxl	Less Share Issue Costs LessShareIssueCosts	-537806	usd
	avxl	Shares Issued Pursuant To Exercise Of Stock Options SharesIssuedPursuantToExerciseOfStockOptions	496923	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8348230	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21320178	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	152205041	usd
	us-gaap	Net Income Loss NetIncomeLoss	-26078997	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21320178	usd
	avxl	Noncash Financing Related Charges NoncashFinancingRelatedCharges	844500	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9316572	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8348230	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	1545081	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-2667844	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	627612	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	109056	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2456965	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2107893	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	877885	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-619386	usd
	avxl	Increase Decrease In Deferred Grant Income IncreaseDecreaseInDeferredGrantIncome	472932	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14282836	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13140439	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18152500	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14399768	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	521441	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	439437	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	496923	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18591937	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14375250	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	4309101	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1234811	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	149157861	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153466962	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153342556	usd
	avxl	Cash Paid For State And Local Minimum Income Taxes CashPaidForStateAndLocalMinimumIncomeTaxes	139577	usd
	avxl	Cash Paid For State And Local Minimum Income Taxes CashPaidForStateAndLocalMinimumIncomeTaxes	141374	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_808_eus-gaap--BasisOfAccounting_zZq4uf2Shwha" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 <span id="xdx_82F_z0wmo129n8G2">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_znYEvP3hVhT9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zV0dfSXhuLel">Basis of Presentation</span> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These accompanying unaudited condensed interim consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim reporting. Accordingly, certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information presented not misleading.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These accompanying unaudited condensed interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2022 was derived from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended September 30, 2022 filed with the SEC on November 28, 2022. The Company follows the same accounting policies in the preparation of interim reports.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating results for the three and six months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_ecustom--LliquidityPolicyTextBlock_zAiBDyICsCZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_znepwWF4jzGl">Liquidity</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the Company’s potential drug compounds are in the clinical development stage and the Company cannot be certain that its research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations. The Company expects the business to continue to experience negative cash flows from operations for the foreseeable future and cannot predict when, if ever, our business might become profitable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the current working capital position will be sufficient to meet the Company’s working capital requirements beyond the next 12 months after the date that these condensed interim consolidated financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials are uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company’s expenditures will vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company’s research and development programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing of future clinical trials.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than our rights related to the Sales Agreement and the Purchase Agreement (as defined below in Note 5), there can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If the Company is not able to obtain the additional financing on a timely basis, if and when it is needed, it will be forced to delay or scale down some or all of its research and development activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--UseOfEstimates_zEswO4DgKpm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_866_zz3cpcMGIZ69">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--ConsolidationPolicyTextBlock_ze8RHSFauRVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zJrCBuITl9dc">Principles of Consolidation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex Australia Pty Limited (“Anavex Australia”), a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company transactions and balances have been eliminated.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zxVD0g3eukN" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_861_zMQJMVFo24xb">Fair Value Measurements</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2023 and September 30, 2022, the Company did not have any Level 3 assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zFLs6IeSvEY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_86C_z6s1GDvjulTl">Basic and Diluted Loss per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period, (2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect of other potentially dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2023 loss per share excludes <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20221001__20230331_pdd" title="Loss per share for potentially dilutive common shares">15,001,613</span> (March 31, 2022: <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20211001__20220331_pdd" title="Loss per share for potentially dilutive common shares">11,510,319</span>) potentially dilutive common shares related to outstanding options and warrants, as their effect was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFRCuf4NZQB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i><span id="xdx_860_zvFoPQmzZ3Ll">Recently Adopted Accounting Pronouncements</span> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance” (“ASU 2021-10”). ASU 2021-10 increases the disclosure requirements for annual reporting periods relating to material government assistance transactions on the entity’s financial statements and any significant terms and conditions of the agreements including commitments and contingencies. The new standard was effective for the Company on October 1, 2022 but only impacts annual financial statement footnote disclosures. The adoption of ASU 2021-10 is expected to impact the disclosures related to the research and development incentive income that the Company receives from the Australian Tax Office (“ATO”) for its clinical trials in Australia.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_849_eus-gaap--UseOfEstimates_zEswO4DgKpm9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i><span id="xdx_866_zz3cpcMGIZ69">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: black"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research and development costs, incentive income receivable, valuation and recoverability of deferred tax assets, stock-based compensation, and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15001613	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11510319	shares
CY2023Q1	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	0	usd
	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	25000	usd
CY2022Q1	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	0	usd
	avxl	Non Operating Income From Grant NonOperatingIncomeFromGrant	0	usd
CY2023Q1	avxl	Deferred Grant Income DeferredGrantIncome	916763	usd
CY2022Q3	avxl	Deferred Grant Income DeferredGrantIncome	443831	usd
CY2023Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	749681	usd
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1483271	usd
CY2022Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	835513	usd
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1646243	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	3.67
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	3.20
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M6D
CY2023Q1	avxl	Accrued Clinical Site And Patient Visits Costs AccruedClinicalSiteAndPatientVisitsCosts	2168950	usd
CY2022Q3	avxl	Accrued Clinical Site And Patient Visits Costs AccruedClinicalSiteAndPatientVisitsCosts	2031105	usd
CY2023Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1572500	usd
CY2022Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1297337	usd
CY2023Q1	avxl	Fixed Contract Accruals FixedContractAccruals	82666	usd
CY2022Q3	avxl	Fixed Contract Accruals FixedContractAccruals	417414	usd
CY2023Q1	avxl	Milestone Based Contract Accruals MilestoneBasedContractAccruals	1041930	usd
CY2022Q3	avxl	Milestone Based Contract Accruals MilestoneBasedContractAccruals	137337	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1956792	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2061760	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6822838	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5944953	usd
CY2023Q1	avxl	Sales Of Agreement Amount SalesOfAgreementAmount	142407882	usd
CY2022Q3	avxl	Sales Of Agreement Amount SalesOfAgreementAmount	142407882	usd
CY2023Q1	avxl	Fair Value Of Initial Commitment FairValueOfInitialCommitment	844500	usd
CY2023Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	30070	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	60140	usd
CY2022Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	16488	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	21333	usd
CY2023Q1	us-gaap	Pension Contributions PensionContributions	56230	usd
	us-gaap	Pension Contributions PensionContributions	99876	usd
CY2022Q1	us-gaap	Pension Contributions PensionContributions	70940	usd
	us-gaap	Pension Contributions PensionContributions	93622	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	160000	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	160000	shares
CY2023Q1	avxl	Warrants Outstanding Weighted Average Exercise WarrantsOutstandingWeightedAverageExercise	3.72
CY2022Q3	avxl	Warrants Outstanding Weighted Average Exercise WarrantsOutstandingWeightedAverageExercise	3.72
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	160000	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P4Y11M1D
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y1M6D
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3970064	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9316572	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4439456	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8348230	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3970064	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4439456	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9316572	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8348230	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	21781736	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0369	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0140	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M9D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y10M24D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8528	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9588	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure

Files In Submission

Name	View Source	Status
0001731122-23-000845-index-headers.html	Edgar Link	pending
0001731122-23-000845-index.html	Edgar Link	pending
0001731122-23-000845.txt	Edgar Link	pending
0001731122-23-000845-xbrl.zip	Edgar Link	pending
avxl-20230331.xsd	Edgar Link	pending
e4668_10-q.htm	Edgar Link	pending
e4668_ex31-1.htm	Edgar Link	pending
e4668_ex31-2.htm	Edgar Link	pending
e4668_ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img_001.jpg	Edgar Link	pending
img_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
avxl-20230331_def.xml	Edgar Link	unprocessable
avxl-20230331_cal.xml	Edgar Link	unprocessable
avxl-20230331_lab.xml	Edgar Link	unprocessable
avxl-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
e4668_10-q_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVXL
ANAVEX LIFE SCIENCES CORP. Stock $avxl

2023 Q2 Form 10-Q Financial Statement

#000173112223000845 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVXL ANAVEX LIFE SCIENCES CORP. Stock $avxl

2023 Q2 Form 10-Q Financial Statement

#000173112223000845 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVXL
ANAVEX LIFE SCIENCES CORP. Stock $avxl